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Abstract
Background: Radiation pneumonia and subsequent radiation lung fibrosis are major dose-limiting complications for 
patients undergoing thoracic radiotherapy. Interleukin-6 (IL-6) is a pleiotropic cytokine and plays important roles in the 
regulation of immune response and inflammation. The purpose of this study was to investigate whether anti-IL-6 
monoclonal receptor antibody (IL-6RA) could ameliorate radiation-induced lung injury in mice.
Methods: BALB/cAnNCrj mice having received thoracic irradiation of 21 Gy were injected intraperitoneally with IL-6RA 
(MR16-1) or control rat IgG twice, immediately and seven days after irradiation. Enzyme-linked immunosorbent assay 
was used to examine the plasma level of IL-6 and serum amyloid A (SAA). Lung injury was assessed by histological 
staining with haematoxylin and eosin or Azan, measuring lung weight, and hydroxyproline.
Results: The mice treated with IL-6RA did not survive significantly longer than the rat IgG control. We observed marked 
up-regulation of IL-6 in mice treated with IL-6RA 150 days after irradiation, whereas IL-6RA temporarily suppressed early 
radiation-induced increase in the IL-6 release level. Histopathologic assessment showed no differences in lung section 
or lung weight between mice treated with IL-6RA and control.
Conclusions: Our findings suggest that early treatment with IL-6RA after irradiation alone does not protect against 
radiation-induced lung injury.
Background
Radiation pneumonia, an interstitial pulmonary inflam-
mation, and subsequent radiation lung fibrosis are signifi-
cant dose-limiting complications and may threaten
quality of life for patients receiving radiation to the tho-
rax. Radiation pneumonia and/or pulmonary fibrosis
occur in approximately 10-20% of patients treated with
thoracic radiotherapy [1]. The incidence of radiation-
induced lung toxicity has increased in recent years due to
more aggressive therapies such as combined chemoradio-
therapy [2]. Clinical symptoms range from cough, fever,
and shortness of breath to death from respiratory failure.
At the cellular and tissue level, radiation pneumonia pres-
ents as an edema of the interstitial space, infiltration of
inflammatory cells, and thickening of the alveolar septa.
Although the molecular mechanism for radiation pneu-
monia is complex and obscure, involvement of proin-
flammatory cytokines, chemokines, and cell adhesion
molecules has been implicated [3,4]. Many investigators
have shown that cytokines play essential roles in the
pathogenesis of radiation pneumonia [5,6]. Interleukin-6
(IL-6), which was originally identified as a B-cell differen-
tiation factor [7], is now known to be a multifunctional
cytokine that regulates acute phase response, immune
response, and inflammation [8,9]. IL-6 is produced by a
variety of cells such as T cells, B cells, monocytes, mac-
rophages, fibroblasts, endothelial cells, and several tumor
cells [10]. Clinical as well as experimental findings have
suggested the involvement of IL-6 as a pro-inflammatory
cytokine in radiation pneumonia [11-14]. Indeed, up-reg-
ulation of IL-6 production has been observed in human
and animals with radiation pneumonia.
In this study, we examined the effect of anti-IL-6 mono-
clonal receptor antibody (IL-6RA) on radiation-induced
lung injury in mice having received lethal irradiation of
the whole thorax. We investigated whether IL-6RA treat-
ment would offer the promise of a new pharmacologic
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intervention strategy for ameliorating radiation-induced
lung injury.
Methods
Mice and irradiation
Eight-week-old specific pathogen-free female BALB/
cAnNCrj mice were obtained from Charles River 1-2
weeks before testing. Mice were maintained according to
the institutional animal care use committee guidelines.
The mice were anesthetized by i.p. injection of pentobar-
bital (40 mg/kg) immediately before irradiation. The
whole thorax was irradiated by 4 MV X-ray from the lin-
ear accelerator (Mitsubishi, EXL-6SP) at a dose of 21 Gy
with a delivered dose rate of approximately 1.8 Gy/min
and a 1.0-cm bolus material on the surface. The field was
2.5 cm in length in the cephalic-tail direction. Survival
and body mass were monitored in IL-6RA treatment (n =
7) or control (n = 8) mice for 200 days after 21 Gy irradia-
tion. For other assays, the animals were sacrificed at a
predetermined time of 50, 100, and 150 days after irradia-
tion (n = 5 per group). Any mouse showing signs of dis-
tress, including lethargy, hunched back, or increased
breathing frequency was sacrificed by overdose of pento-
barbital.
Injection of IL-6RA(MR16-1)
Basic characterizations of the rat anti-mouse IL-6 recep-
tor monoclonal antibody, MR16-1, have been detailed in
previously published reports [15]. Immediately and 1
week after irradiation, mice were intraperitoneally
administered with a single doses of MR16-1 (8 mg/kg
body weight) or with the same volume and concentration
of purified rat IgG (ICN Biomedicals, Inc).
Circulating IL-6 and SAA analysis
Blood samples were collected via cardiac puncture at the
time of euthanasia, and plasma was obtained after micro-
centrifugation at 4,000 g for 5 min. Plasma concentrations
of IL-6 (Pierce Endogen Co. Ltd) and serum amyloid A
(SAA) (Biosource) were measured by commercial
enzyme-linked immunosorbent assay (ELISA) kits
according to the instructions of the manufacturer.
Lung hydroxyproline determination
Collagen deposition was estimated by determining the
hydroxyproline content of the left lung. Samples were
hydrolyzed with 6 N HCl at 105°C for 18 h. The samples
were resuspended in 2 ml of deionized water and 1 ml of
chloramine T dissolved in 5 mol/L sodium acetate/10%
isopropanol. Next, 0.5 ml of Ehrlich's reagents were
added, mixed, and incubated at 65°C for 10 min. The
absorbance of the solutions at 562 nm was determined.
The hydroxyproline values of the samples were calculated
according to comparing to the standard curve. Data were
corrected for total left lung wet weight.
Histologic analysis
For histological examination, the lung tissue was fixed in
10% neutral-buffered formalin solution, embedded in
paraffin wax, sectioned (5 μm thickness), and stained
with haematoxylin and eosin (H&E) or Azan. For H&E
staining, we evaluated an edema of the interstitial space,
infiltration of inflammatory cells, thickening of the alveo-
lar septa, and vessel thrombosis. The amount of pulmo-
nary interstitial collagen was determined by Azan
staining. The area stained blue (collagen fibers) was eval-
uated under a microscope.
Statistical analysis
The statistical significance was tested by means of the
Kaplan-Meier method and the log-rank test for survival
analysis. Comparison of the other assays between two
groups was performed using non-parametric the Mann-
Whitney U-test because of small number. A p-value of
less than 0.05 was considered to be statistically signifi-
cant.
Results
Survival and body weight
We first evaluated whether IL-6RA administration leads
to increased survival of mice exposed to lethal thoracic
irradiation and found that the mice treated with IL-6RA
did not survive significantly longer than the rat IgG con-
trol (Figure 1A). Growth expressed as total body weight is
presented graphically in Figure 1B, showing that the mice
treated with IL-6RA tended to weigh more than the rat
IgG control mice.
IL-6 and SAA concentrations
Protein levels of IL-6 and SAA, one of the major acute-
phase proteins in mammals, were determined by means
of specific ELISA in plasma from irradiated mice (Figure
2). The mice treated with IL-6RA showed a marked
reduction of the radiation-induced increase in IL-6 pro-
teins in plasma as compared with the control group 50
days (25.1 ± 10.5 versus 101.6 ± 31.2 pg/ml, p < 0.05) and
100 days (48.5 ± 17.2 versus 446.3 ± 96.9 pg/ml, p < 0.05)
after irradiation (Figure 2A). After 150 days, however, a
marked, but not statistically significant, up-regulation in
IL-6 was observed in mice treated with IL-6RA in com-
parison with the rat IgG group (247.6 ± 116.6 versus
116.9 ± 56.4 pg/ml). As shown in Figure 2B, administra-
tion of IL-6RA significantly suppressed the radiation-
induced increase in SAA proteins in plasma compared
with the control group after 150 days (10.9 ± 8.8 versus
101.1 ± 32.7 μg/ml, p < 0.05). Non-irradiated mice with-
out any antibody in a previous study showed low IL-6 and
SAA protein levels in plasma (25.2 ± 7.7 pg/ml and 8.2 ±
4.4 μg/ml, respectively).Ogata et al. Radiation Oncology 2010, 5:26
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Wet lung weights and hydroxyproline content
Lung weight was measured to assess pulmonary edema
and consolidation (Figure 3A) and after lung irradiation a
gradual, time-dependent increase in lung weight was
observed in the IL-6RA group as compared with the con-
t r o l  g r o u p .  H o w e v e r ,  t h e  d i f f e r e n c e  i n  l u n g  w e i g h t
between the two groups did not become significant at any
time after irradiation.
Lung hydroxyproline measurements were analyzed for
the quantification of collagen deposition (Figure 3B) and
no statistically significant difference in hydroxyprolin
content between the two groups was detected after irra-
diation.
Histologic analysis
The time course of H&E and Azan staining in the lung
tissue after irradiation is shown in Figures 4 and 5, dem-
onstrating that the extent and severity of lung damage
was not significantly reduced in the IL-6RA group in
comparison with the control group.
Figure 1 Kaplan-Meier analysis of survival curves and body weights for IL-6RA- (white circle) and IgG control (black circle)-injected mice. 
(A) Survival curves. The p value was calculated with the log-rank test. Kaplan-Meier plots were calculated from data for 7 IL-6RA-treated mice and 8 
nontreated mice. (B) Body weights. Data are presented as means + SD.
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Figure 2 Effects of IL-6RA treatment in lungs of lethally irradiated IL-6RA (white square) and IgG control (black square) mice on radiation-
induced increases in IL-6 (A) and SAA (B) production. Each bar represents the mean ± SD (n = 5 per group). Asterisks indicate statistical significance. 
Dotted line represents each from average value of non-irradiated mice + SD to average value of them -SD.
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Discussion
Radiation pneumonia and subsequent radiation lung
fibrosis are major dose-limiting complications for
patients undergoing thoracic radiotherapy. Recent
research findings support the existence of a mechanism
of cellular interaction between lung parenchymal cells
and circulating immune cells mediated through various
cytokines such as proinflammatory cytokines, chemok-
ines, adhesion molecules, and profibrotic cytokines [3,4].
Since IL-6 is a pleiotropic cytokine that plays important
roles in the regulation of immune response and inflam-
mation, IL-6 receptor monoclonal antibody treatment
has been identified as a promising treatment for Castle-
man's disease, rheumatoid arthritis, juvenile idiopathic
arthritis, and Crohn's disease [16-19]. IL-6 has also been
implicated in the pathogenesis of radiation pneumonia
[11-14] and is synthesized by type II pneumocytes, alveo-
lar macrophages, T lymphocytes, and lung fibroblasts [5].
Figure 3 Effects of IL-6RA treatment on radiation-induced lung injury indices. (A) Lung weight after 21 Gy of single irradiation to whole thorax 
with (white square) or without (black square) IL-6RA treatment. (B) Hydroxyproline levels in lung homogenates obtained from IL-6RA injected mice 
(white square) or control (black square). Data obtained from 5 animals in each group are presented as means ± SD. Dotted line shows each from mean 
value of non-irradiated mice + SD to mean value of them -SD.
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Figure 4 Histological analyses using H&E staining for irradiated 
murine lung tissue.
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Figure 5 Histological analyses using Azan staining for irradiated 
murine lung tissue.
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We therefore hypothesized that blockage of the IL-6 sig-
naling pathways may offer an attractive therapeutic target
for the amelioration of radiation-induced lung injury.
IL-6RA treatment was found to inhibit a radiation-
induced increase in IL-6 proteins 50 and 100 days after
irradiation. Moreover, after 150 days IL-6RA significantly
suppressed a radiation-induced increase in inflammatory
m a r k er  SAA pr ot e ins  in plasm a  as c o m pa r ed wit h t he
control group. Acute phase protein SAA is known as a
sensitive systemic marker of inflammation and tissue
damage [20]. Further, IL-6 plays an important role in the
synergistic induction of the SAA gene and the anti-IL-6
receptor monoclonal antibody inhibits the synergistic
induction of SAA [21]. These findings indicate that IL-
6RA has some beneficial effects. In our study, however,
no significant difference was observed in severity of lung
d a m a g e  o r  l e n g t h  o f  s u r v i v a l  b e t w e e n  I L - 6 R A  t r e a t e d
mice and control.
One possible explanation for this finding is that long-
term continuous administration of IL-6RA may be neces-
sary for reducing lung toxicity. Rube et al. showed that
radiation-induced release of IL-6 in the bronchiolar epi-
thelium of C57BL/6J mice was detected a few hours and
several weeks after irradiation (peak at 8 weeks) [14].
Radiation-induced lung injury is a chronic phenomenon
mediated by various cells such as inflammatory cells
responding to the release or activation of downstream
cytokines, growth factors, or chemokines. Anscher et al.
reported long-term (6-month) administration of the
small molecule inhibitor of TGF-beta was more effective
in reducing radiation-induced lung toxicity than short-
term (3-week) administration [22]. Long-term IL-6RA
treatment following irradiation may therefore ameliorate
radiation-induced lung injury. Because we were con-
cerned that repeated treatment with rat antibody would
result in the production of mouse anti-rat antibodies
against the rat antibody, we could not administer IL-6RA
more than twice. In a previous pilot study we examined
plasma IL-6 levels in mice having received only radiation
of 21 Gy and confirmed that radiation-induced IL-6 pro-
duction in Balb/c mice reached a peak 1 week after irradi-
ation (data not shown). The reason for the choice of this
time point was that we wanted to inhibit acute interstitial
inflammation.
A marked up-regulation of IL-6 was observed in mice
treated with IL-6RA in comparison with the rat IgG
group 150 days after irradiation. This result may be
explained by the fact that the time until the peak concen-
tration of IL-6 in IL-6RA-treated mice had changed due
to the inhibition of autocrine production of IL-6. Rube et
al. reported radiation-induced IL-6 production in
C57BL/6J mice reached two peaks a few hours and 8
weeks after irradiation [14]. However, marked mouse
strain differences in cytokine levels and patterns may
occur such as in the histological configuration of radia-
tion-induced lung injury [23]. BALB/c mice were chosen
for this study because this strain is known to possess
comparable radiosensitity [24]. We hypothesized that use
of a different mice strain might cause changes in the
pathogenesis of radiation pneumonia and thus alter the
survival of mice receiving lethally irradiation of the whole
thorax. A significant increase in SAA was observed in
mice treated with IgG in comparison with the IL-6RA
group 150 days after irradiation, whereas the mice treated
with IL-6RA showed a significant induction of IL-6 in
comparison with the rat IgG group. This result may be
explained by the fact that signal transduction of IL-1 or
TNF-alpha is more strongly involved in the regulation of
SAA production than that of IL-6 [25]. These findings
suggest that elevation of IL-6 was not strongly implicated
in the pathogenesis of radiation pneumonia but was
rather derived from the development of radiation pneu-
monia. Although a limitation of our study is that a rela-
tively small number of mice were used, it is clear from
these results that further intensive study is warranted.
There is concern that intervention to prevent radiation-
induced toxicity may also serve to protect cancer because
clinical investigations found increased serum IL-6 levels
in cancer patients [26]. Aberrant production and signal-
ing of circulating IL-6 has been implicated in tumor gen-
eration and poor disease outcome in various cancers [27].
Since blockade of IL-6 signaling by shRNA inhibits lung
adenocarinoma cell growth [28], IL-6RA treatment may
inhibit radiation-induced lung toxicity as well as tumor
proliferation.
Conclusions
To summarize, the findings presented here suggest that
early intervention using IL-6RA could not ameliorate
radiation-induced lung injury. Additional work is needed
to determine the optimal timing and duration for therapy
using this approach to the prevention of lung injury after
radiation therapy. Despite the negative findings of our
study, further intensive studies are needed into strategies
for inhibition of cytokine signaling as a way to ameliorat-
ing lung toxicity from radiotherapy.
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